View Older Stories View More Recent Stories
-
Morgan Stanley on Medtronic, Inc. (MDT): 'Positive signs, though slightly soft organic'
-
Leerink Partners Positive on Medtronic, Inc. (MDT)
-
Goldman on Medtronic, Inc. (MDT), 'believe investors had expected total organic growth acceleration to follow the strong performance in CAS'
-
Raymond James on Medtronic, Inc. (MDT) Earnings: 'All in, this result and guide fell short of our elevated expectations'
-
Stifel Reiterates Hold Rating on Medtronic, Inc. (MDT)
-
Mizuho on Medtronic, Inc. (MDT): 'Largely Inline Print Likely Overshadowed by New Board Appointees'
-
Medtronic appoints two directors, forms board committees after Elliott talks
-
Medtronic (MDT) Tops Q1 EPS by 3c, Beats on Revenue; Offers FY26 EPS Guidance
-
Medtronic adds board members after Elliott becomes major shareholder - report
-
Medtronic (MDT) to add Directors as Elliott becomes major shareholder - WSJ
-
Medtronic poised for Q1 beat on strong product cycle, currency tailwinds
-
Raymond James on Medtronic, Inc. (MDT): 'Expecting a Strong F1Q; Consistency and Margins are Key'
-
Goldman now owns a big slug of this med-tech stock, possibly for an activist
-
Needham Reiterates Hold Rating on Medtronic, Inc. (MDT)
-
Medtronic (MDT) Declares $0.71 Quarterly Dividend; 3.1% Yield
-
Orchestra BioMed raises $111 million through equity offerings and partnerships
-
Ligand and Medtronic invest $70 million in Orchestra BioMed
-
Medtronic gets CE Mark for expanded MiniMed 780G diabetes system uses
-
Goldman Sachs Reiterates Sell Rating on Medtronic, Inc. (MDT)
-
Raymond James Reiterates Market Perform Rating on Medtronic, Inc. (MDT)
-
William Blair Out Positive on Medtronic, Inc. (MDT)
-
JPMorgan Reiterates Neutral Rating on Medtronic, Inc. (MDT)
-
BofA Securities Reiterates Buy Rating on Medtronic, Inc. (MDT)
-
BTIG Comments on Medtronic, Inc. (MDT)
-
Evercore Comments on Medtronic (MDT)
-
Citi Opens 90d Upside Cat Watch on Medtronic, Inc. (MDT)
-
Leerink Partners: 'We expect MDT to trade higher tomorrow'
-
Medtronic (MDT) gains on RDN NCA proposal
-
Medtronic names Chad Spooner CFO of MiniMed ahead of spinoff
-
Evercore Lists Additions to TAP Outperform List of Life Science & Diagnostic Tools Names
-
Wolfe Research Upgrades Medtronic, Inc. (MDT) to Peerperform
-
Strong AI adoption and monetization to drive the next leg of AI rally, says UBS
-
Medtronic (MDT) appoints Joon Lee to its Board
-
Piper Sandler's Key MedTech Takeaways From ADA 2025
-
RBC Capital on Medtronic, Inc. (MDT): 'RDN Survey Points To Significant Unlocked Opportunity'
-
Mizuho survey highlights upside in this MedTech stock
-
Leerink starts coverage on Boston Scientific and Medtronic with bullish ratings
-
Leerink Partners Starts Medtronic, Inc. (MDT) at Outperform
-
Medtronic (MDT) names spinoff diabetes company MiniMed
-
Needham Reiterates Hold Rating on Medtronic, Inc. (MDT)
-
Evercore ISI on Boston Scientific (BSX) Read-through: 'This should be a positive for ABT & MDT'
-
JPMorgan on Boston Scientific (BSX): 'We’d be buyers of BSX on any material weakness'
-
Medtronic, Inc. (mdt) PT Raised to $92 at Truist Securities
-
Medtronic, Inc. (MDT) PT Lowered to $101 at RBC Capital
-
Stifel Reiterates Hold Rating on Medtronic, Inc. (MDT)
-
Bernstein on Medtronic, Inc. (MDT): 'Positive Momentum; We Like the Diabetes Split-Off'
-
Evercore ISI Removes Medtronic, Inc. (MDT) from TAP List
-
Medtronic, Inc. (MDT) PT Lowered to $103 at Evercore ISI
-
Medtronic, Inc. (MDT) PT Lowered to $98 at Citi
-
Medtronic (MDT) to separate Diabetes business
